Effect of probucol on repeat revascularization rate after percutaneous transluminal coronary angioplasty (from the Probucol Angioplasty Restenosis Trial [PART]).
To address the issue of whether probucol reduces clinical events after percutaneous transluminal coronary angioplasty (PTCA), we surveyed clinical status at 1 year after PTCA of 101 patients who had entered the Probucol Restenosis Angioplasty Trial. Repeat angioplasty at index lesions were required in 5 patients in the probucol group and in 12 in the control group, suggesting that probucol administered beginning 4 weeks before PTCA reduces repeat revascularization rates for 1 year.
Daida
H
H
Department of Cardiology, Juntendo University, Tokyo, Japan. daida@med.juntendo.ac.jp
Kuwabara
Y
Y
Yokoi
H
H
Nishikawa
H
H
Takatsu
F
F
Nakata
Y
Y
Kutsumi
Y
Y
Oshima
S
S
Nishiyama
S
S
Ishiwata
S
S
Kato
K
K
Nishimura
S
S
Miyauchi
K
K
Kanoh
T
T
Yamaguchi
H
H
D015906:Angioplasty, Balloon, Coronary; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D003327:Coronary Disease / Q000517:prevention & control* / Q000628:therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011341:Probucol / Q000627:therapeutic use*; D011446:Prospective Studies; D055502:Secondary Prevention
D000924:Anticholesteremic Agents; D011341:Probucol